Therefore, the detection of ALK rearrangements by targeted next-generation sequencing, such as DNA-based and RNA-based NGS, may be a good complementary approach to precisely identify rare or novel ALK fusion variants to guide targeted therapy with ALK inhibitors in patients with NSCLC (13–15). Here, ALK is linked to non-small cell lung carcinoma.